Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 2008

View Archived Issues

Alimera initiates enrollment in clinical trial of Medidur FA in conjunction with Lucentis

Rabeximod active in models of autoimmune diseases

Phase I study of Nexagon for healing after laser eye surgery recruiting patients

CY-503 evaluated in phase II stage IV malignant melanoma trial

DMXB-Anabaseine improves negative symptoms in phase II schizophrenia trial

Mechanisms behind anti-atherosclerotic effects of EP-80317 studied in ApoE-/- mice

Cholesterol lowering with AVE-5530 described in animals

Pipex receives FDA orphan drug designation for oral tetrathiomolybdate for IPF

FDA approves Taclonex Scalp for psoriasis of the scalp

Piramal Life Sciences initiates phase I trials with P-1736 for type 2 diabetes

Oncolytics initiates enrollment in REO 012 clinical trial of Reolysin and cyclophosphamide

Virostatics initiates dosing in phase IIa trial of VS-411 in HIV

NovaBay reports results from phase I trial of NVC-422 in prevention of CAUTI

Takeda and Affymax report results from three phase II trials of Hematide

New agents for infectious diseases described in recent CSIR and GSK patents

FDA grants marketing approval to Novalar's dental anesthetic reversal agent OraVerse

New therapeutic options for cancer reported in recent patents

Crucell initiates phase II clinical study in the Philippines of rabies monoclonal antibody

Ambrilia presents positive final phase III results for Octreotide C2L

ChemoCentryx commences clinical trial for CCX-354

Novel sEH inhibitor shows benefit in mouse model of obesity

FDA approves Seroquel for maintenance treatment in bipolar disorder

FDA grants orphan drug designation for SB-1518 in myeloproliferative disorders

Pharmasset doses two additional cohorts in R-7128 chronic hepatitis C trial

Intercell to acquire Iomai to expand late-stage product pipeline

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...